NCT06398444View on ClinicalTrials.gov

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

June 11, 2024

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2029

Conditions
Advanced Neuroendocrine Neoplasm
Interventions
DRUG

Lutetium[177Lu] Oxodotreotide Injection

Participants will receive 7.4GBq (200mCi) Lutetium\[177Lu\] Oxodotreotide Injection every 8 weeks.

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Sinotau Pharmaceutical Group

INDUSTRY

NCT06398444 - A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms | Biotech Hunter | Biotech Hunter